中国抗体-B(03681)：SM17在中国治疗中重度特异性皮炎的 1B期临床试验的积极顶线结果
智通财经APP讯，中国抗体-B(03681)发布公告，
SM17在中国治疗特异性皮炎的1B期临床试验的积极顶线结果，尤其在抗瘙痒效果方面展现了差异化疗效。
本项1b期临床研究是一项随机双盲、多中心、安慰剂对照入组临床试验，旨在研究SM17的用药安全性、耐受性及药代动力学特征，并初步验证SM17对于中重度 AD患者的有效性。1b期研究共纳入32例中重度AD患者，按3:3:2的比例随机接受高剂量SM17(600mg)、低剂量SM17(200mg)或安慰剂治疗，试验周期包括12周的治疗期及随后4周的停药维持╱安全随访期。本次试验的主要终点为SM17的安全性性质，评估内容为16周期间的耐受性、治疗引致不良事件(TEAE)发生率、生命体征及实验室检查指标的变化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10